Hybrid polyketide-nonribosomal peptide compound streptolydigin (Fig. 1A) , produced by Streptomyces lydicus, is a member of the tetramic acid family (21) . It is a potent inhibitor of bacterial RNA polymerase (RNAP) (20, 22, 23) . In addition, streptolydigin has been shown to inhibit terminal deoxynucleotidyltransferase, an enzyme found in large amounts in leukocytes from patients with acute lymphoblastic leukemia or with rare cases of acute and chronic myelocytic leukemia (6, 7) . The streptolydigin biosynthesis gene cluster from S. lydicus NRRL2433 has been recently characterized, and the involvement of a hybrid polyketide synthase (PKS)/nonribosomal peptide synthetase (NRPS) system has been confirmed. In addition, genes encoding proteins involved in secretion, pathway regulation, tailoring modification, and precursor supply were identified (16) . Among the precursor supply-associated genes, slgZ and slgM, encoding an asparaginyl-tRNA synthetase like enzyme and a methyltransferase, respectively, have been proposed to be involved in the tailoring modification of precursor 3-methyl-aspartate (16) . In this communication, we provide further experimental evidence of the role of these two genes in precursor supply for streptolydigin biosynthesis.
SlgZ shows similarity to class IIb aminoacyl-tRNA synthetases. However, this was a surprising finding, since, apparently, no aminoacyl-tRNA synthetase was anticipated to be necessary for streptolydigin biosynthesis. To the best of our knowledge, few aminoacyl-tRNA synthetases have been demonstrated to be involved in antibiotic biosynthesis; such synthetases include seryl-tRNA synthetase VlmL from Streptomyces viridifaciens MG456-hF10 (8) and aminoacyl-tRNA synthetase-like cyclodipeptide synthases such as AlbC, which uses aminoacyltRNAs as substrates to catalyze the formation of the diketopiperazine peptide bonds (10) . AlbC participates in the biosynthesis of valinomycin, catalyzing the transfer of the seryl residue from seryl-tRNA to the hydroxyl group of isobutylhydroxylamine (9) . Nevertheless, SlgZ also shows similarity to archaeal asparaginyl-tRNA synthetases and, in particular, to a kind of such enzymes that contains the catalytic core of asparaginyl-tRNA synthetases but lacks the N-terminal anticodonbinding site (Fig. 1B) . This kind of truncated form of asparaginyl-tRNA synthetases has been shown to produce asparagine by amidation of aspartic acid. In particular, this activity has been demonstrated in the case of AsnRS2 from Pyrococcus abyssi. This proved that AsnRS2 is the archaeal orthologue of the bacterial ammonia-dependent asparagine synthetase A (19) . The role of SlgZ in streptolydigin biosynthesis was therefore further investigated by deleting slgZ from S. lydicus by intergeneric conjugation from Escherichia coli ET12567(pUB307) and using p⌬slgZHyg (Table 1) . A single-crossover strain, which was apramycin and hygromycin resistant, was grown in the absence of antibiotic selection, and then colonies were screened for hygromycin sensitivity and apramycin resistance as a consequence of a double recombination event. This approach led to the mutant SLMZ ( Fig. 2A) .
Analysis of the products accumulated by mutant SLMZ (Fig.  2B) showed a novel compound (3) with an ultrahigh-performance liquid chromatography (UPLC) retention time of 6.1 min. Upon mass spectrometry (MS) analysis, this peak showed two ions with m/z 587 and 473 ([M ϩ H] ϩ ), corresponding to the unfragmented compound and the aglycon fragment ions, respectively. The structural elucidation of this compound was carried out using one-dimensional (1D) 1 H, two-dimensional (2D) 1 H cooler synchrotron (COSY), 1 H, 13 C heteronuclear single-quantum coherence (HSQC)-edited, and heteronuclear multiple-bond correlation (HMBC) nuclear magnetic resonance (NMR) experiments. This allowed us to identify the compound as streptolydigin B, a derivative of streptolydigin with a tetramic acid lateral side chain derived from glutamate instead of 3-methyl-aspartate (Fig. 1A) . Production of streptolydigin in mutant SLMZ was restored by introduction of plasmid pEM4TslgZ, containing slgZ under the control of the ermE* promoter (Fig. 2B) . All these experiments demonstrate the utilization of glutamate instead of 3-methyl-aspartate as the substrate by the streptolydigin NRPS complex and conse-quently show a certain degree of substrate flexibility. This incorporation might be sustained by the 2-fold increase in the glutamate pool of SLMZ compared with that of the S. lydicus wild type, observed when the intracellular amino acid pools were determined by growing the strains in a minimal medium with NH 4 Cl as the nitrogen source, medium that sustains the production of streptolydigin by S. lydicus. The analysis of glutamate pools was performed by amino acid derivatization with phenylisothiocyanate and UPLC analysis as described previously (1) .
The fact that SLMZ incorporates glutamate is a clear suggestion that the SlgZ protein acts as an aminotransferase, converting 3-methyl-aspartate into 3-methyl-asparagine, in a manner similar to that of AsnR2 of P. abyssi (19) . Therefore, we propose that SlgZ is not a classical asparaginyl-tRNA synthetase but a 3-methyl-asparagine synthetase.
The antibiotic activity of streptolydigin B was tested and compared with that of streptolydigin by a bioassay as previously described (16) . Streptolydigin B showed less activity against Streptomyces albus than streptolydigin (Fig. 2C) . This indicates that the modification of the tetramic acid lateral side chain, and in particular the replacement of the acetamide moiety by a carboxyl group, reduces the antibacterial activity of this compound. This effect is supported by the observation of the nitrogen of this moiety interacting with the Thermus thermophilus RNAP ␤Ј subunit Asn729 and the fact that the RNAP is less sensitive to tirandamycin (22) , which also lacks the acetamide group. The effect of SlgZ on the production of streptolydigin was assessed by overexpressing the corresponding gene in the S. lydicus wild-type strain. We used two plasmids, pEM4TslgZ and pEM4HTslgZ (Table 1) , both carrying slgZ under the control of the ermE* promoter but each carrying a different antibiotic marker, that for apramycin in pEM4TslgZ and that for hygromycin in pEM4HTslgZ. Expression of slgZ by using pEM4TslgZ had no apparent effect on streptolydigin production, while its expression by using pEM4HTslgZ led to a 1.5-fold increase in streptolydigin production (Fig. 2D) .
SlgM is a putative methyltransferase that contains the methyltransferase-11 signature domain present in S-adenosylmethionine (SAM)-dependent methyltransferases of this family of enzymes (pfam 08241). An slgM mutant was generated by gene disruption using pOJM (Table 1) . Transconjugants were selected for resistance to apramycin. Analysis of the products accumulated by mutant SLMM showed no production of streptolydigin or any other derived compound (data not shown). This was an unexpected result, since, as previously reported, demethyl-streptolydiginone was isolated from mutant SLM7H13 (16), with L-rhodinose biosynthesis genes slgS3 to slgS7 deleted, and it was expected to be accumulated by SLMM. Accumulation of a streptolydigin intermediate or derivative compound would confirm the participation of SlgM in tailoring modification, as has been the case with other methyltransferases involved in the biosynthesis of polyketides and nonribosomal peptide compounds (17, 18) . However, the lack of antibiotic production in mutant SLMM is in agreement with the results obtained by inactivating lipMt in the tetramic acid ␣-lipomycin biosynthesis gene cluster from Streptomyces aureofaciens Tü117 (3). In that case, the lack of LipMt abolished ␣-lipomycin production and led to the authors of that study to propose that the methylation event occurs on an NRPS-bound glutamic acid substrate (3). Curiously, in the ␣-lipomycin biosynthesis gene cluster lipMt, lipX2, and lipNrps are organized in the same manner as slgM, slgL, and slgN2 are in the streptolydigin gene cluster. The proteins encoded by these genes in each pathway are homologues and are proposed to perform equivalent activities (3, 16) .
The absence of demethyl-streptolydiginone in cultures of SLMM led us to propose also a bound 3-methyl-asparagine- (Fig. 1C) . This N-methylation step might be required for the correct condensation of the amino acid-NRPS bound to the already formed polyketide backbone. The absence of SlgM might imply the presence of a bound 3-methyl-asparagine-NRPS (with a free amino group), thus blocking the biosynthetic pathway (or, less probably, generating an unstable intermediate). Otherwise, if not blocked, the streptolydigin NRPS should incorporate glutamate, thus generating streptolydigin B (as in mutant SLMZ), a compound that is not produced by mutant SLMM. The bound 3-methylasparagine-NRPS substrate might arise from the incorporation of 3-methyl-aspartate into the NRPS, followed by its amidation by SlgZ (Fig. 1C) , since purified SlgZ retains a slight level of aspartate amidation activity but is unable to amidate free 3-methyl-aspartate (data not shown). Production of streptolydigin in mutant SLMM was restored by introduction of plasmid pEM4TslgM, containing slgM under the control of the ermE* promoter.
Considering the positive effect of expressing slgZ in the S. lydicus wild-type strain on streptolydigin production, the effects of expressing slgM and both slgZ and slgM in this strain were analyzed. The plasmids used to carry on these experiments were pEM4TslgM, pEM4HTslgM, pEM4TslgZM, and (1) and streptolydigin B (2) against S. albus. Each paper disk was soaked with 2 g of the corresponding compound. Control (C), without antibiotic. (D) Effect of slgZ, slgM, and slgZ-slgM overexpression in S. lydicus on streptolydigin production. Cultures were performed on R5A solid media, and streptolydigin production was determined by high-performance liquid chromatography (HPLC) analysis. Experiments were run in triplicate. pEM4HTslgZM (Table 1 ). The use of pEM4TslgM and pEM4HTslgM led to moderate increases in streptolydigin production (2-and 1.1-fold, respectively) (Fig. 2D ). However, a cooperative effect was observed by expressing slgZ and slgM by using pEM4TslgZM and pEM4HTslgZM. These coexpression experiments led to 3-and 2.1-fold increases in production, respectively (Fig. 2D) .
One issue remains to be clarified: the origin of demethylstreptolydiginone isolated and characterized from mutant SLM7H13 (16) . In this mutant, two nonglycosylated compounds were isolated: demethyl-streptolydiginone and streptolydiginone. The initial proposal for the streptolydigin pathway assumed that demethyl-streptolydiginone was the precursor of streptolydiginone to be N methylated by SlgM. The results obtained in this work with mutant SLMM prove that demethyl-streptolydiginone is not the substrate for SlgM. However, demethyl-streptolydiginone could be derived from streptolydiginone by an S. lydicus demethylase. Demethylation activity, performed by family 51 of cytochrome P450s, of different structural types of bioactive compounds is widely distributed among actinomycetes and has been reported from several Streptomyces and Mycobacterium species. In particular, drug N demethylases have been reported from Streptomyces griseus ATCC 13273 (5), Streptomyces platensis NRRL2364 (4), and other Streptomyces spp. (11) .
